Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Jun 07, 2020 10:46am

115 Views

Post# 31121514

RE:Taxes

Seems their net share count either increased or stayed the same with the selling of shares and excersizing of the options, not a big deal at all.................Stauffer coming on board mus like what he sees and potential.....

Amigo11 wrote: Its also quite possible they needed money for as simple a reason as income tax-the dates of sale line up within a week of ghe June 1 T1 deadline.These guys have obligations like payments,ex wives and taxes like the rest of us !I gotta say tho ,it would have been great to see Insider buying !!!

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features